[pubmed] Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, an
Posté : 06 sept. 2021 12:00
Front Cardiovasc Med. 2021 Aug 16;8:714460. doi: 10.3389/fcvm.2021.714460. eCollection 2021.
ABSTRACT
The neuromuscular adverse events of immune checkpoint inhibitor (ICI) treatment include myositis, polymyalgia rheumatica, myocarditis, and myasthenia syndrome. We report a 47-year old female presenting with external ophthalmoplegia, generalized muscle weakness, and third-degree atrioventricular block 4 weeks after toripalimab treatment for metastatic thymoma. Creatine kinase was elevated to 25,200 U/l and cardiac troponin I to 2.796 ng/ml. Autoantibody profiling shows positive anti-ryanodine receptor and anti-acetylcholine receptor antibodies and negative myositis specific antibodies. Repetitive nerve stimulation did not reveal decrement of compound muscle action potentials. Pulse methylprednisolone and immunoglobulin infusion, together with temporary pacemaker insertion normalized her muscle enzyme levels and cardiac rhythm. This is the first report of overlaping neuromuscular adverse event of toripalimab.
PMID:34485412 | PMC:PMC8415306 | DOI:10.3389/fcvm.2021.714460
Source: https://pubmed.ncbi.nlm.nih.gov/3448541 ... 5&v=2.14.5